A phase III trial of ALN-AS1 in acute hepatic porphyria patients

Trial Profile

A phase III trial of ALN-AS1 in acute hepatic porphyria patients

Planning
Phase of Trial: Phase III

Latest Information Update: 03 Dec 2016

At a glance

  • Drugs Givosiran (Primary)
  • Indications Acute intermittent porphyria; Liver disorders; Porphyria
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Dec 2016 According to an Alnylam Pharmaceuticals media release, company plans to initiate this study in late 2017.
    • 06 May 2016 New trial record
    • 02 May 2016 Alnylam Pharmaceuticals plans to initiate this trial in 2017 if the phase I trial results are positive, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top